Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort-Reference-Cited by-同舟云学术

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort

Published:2016-12 Issue:6 Volume:70 Page:963-970
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Smith Matthew R.,Antonarakis Emmanuel S.,Ryan Charles J.,Berry William R.,Shore Neal D.,Liu Glenn,Alumkal Joshi J.,Higano Celestia S.,Chow Maneval Edna,Bandekar Rajesh,de Boer Carla J.,Yu Margaret K.,Rathkopf Dana E.

Publisher

Elsevier BV

Subject

Urology

Reference21 articles.

1. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets;Chi;Eur Urol,2009

2. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer;Smith;J Clin Oncol,2005

3. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer;Smith;Cancer,2011

4. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time;Smith;J Clin Oncol,2013

5. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Prostate cancer, v.1.2016. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Working title: Molecular involvement of p53‐MDM2 interactome in gastrointestinal cancers;Cell Biochemistry and Function;2024-06

2. Synthesis and application of clinically approved small-molecule drugs targeting androgen receptor;Bioorganic Chemistry;2024-02

3. Design and synthesis of fluorine aromatic scaffolds containing drugs approved by the US FDA from 2002 to 2022;Results in Chemistry;2024-01

4. Synthesis and clinical application of small-molecule drugs approved to treat prostatic cancer;European Journal of Medicinal Chemistry;2023-12

5. Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy;Annals of Medicine;2023-11-08